Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

Summary

The purpose of the trial is to evaluate the safety and efficacy of MarzAA for on-demand treatment and control of bleeding episodes in hemophilia A or B patients with inhibitors compared with their standard of care (SOC).

Timeline

Start

2021-05-04

Primary completion

2021-11-15

Completion

2021-12-01

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision (not a safety decision)”

Drugs

Indications